GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

GenSight Biologics Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch

GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ®

GenSight Biologics Announces Successful Manufacture of LUMEVOQ® GMP Batch

GenSight Biologics Withdraws its EMA Application for LUMEVOQ®

GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial